Vaccines

Vaccination for VZV and HPV requires special consideration in immunocompromised patients. They are at risk for more severe viral illnesses if not immune, but they may also have decreased response to, and increased adverse effects from, vaccines.

A glimpse into FDA advisor perspective just weeks before EUAs are anticipated to be sent.

The presenting IDWeek author discusses the implication of promising phase 3 data for a new HBV vaccine.

The conclusion to the independent safety review punctuates a 50-day period of scrutiny and discussion around 2 non-fatal adverse events reported in patients.

In an effort to expand serotype coverage beyond 13, a 20-valent pneumococcal conjugate vaccine, PCV20, is currently in development.

New head-to-head phase 3 data show a promising potential new HBV vaccine may join the market in the near future.

A vaccine developer joins for a firsthand discussion on the development, research, and distribution process.

Pfizer anticipates to have completed FDA-mandated safety data a month from now. An EUA application should shortly follow.

The Meharry and Vanderbilt-based expert shares insights into reaching less trustful populations on the first podcast episode.

In consideration of the idea that the pandemic may lead to greater knowledge and adoption of preventive health measures.

Numerous candidates are in late-stage assessment. An expert shares what the diverse agents should show before being considered for regulation.

The new guidance bucks against the White House's campaign message of an available prophylaxis by the election.

Perspective on the ongoing independent safety reviews for one of the more promising vaccine candidates.

Why the AstraZeneca & Oxford University trial's pause due to an adverse event was a sign to Fauci the vaccine monitoring systems are working.

The country is split on certain strategies and a potential vaccine. Here's why the message needs to go from national to regional.

Is it still safe to take your child to get a vaccine during the pandemic? According to experts, there are safety measures in place for this critically important task.

J&J is evaluating both 1- and 2-dose regimens of the adenovirus vector investigational vaccine.

What the AstraZeneca vaccine research pause meant for physician-patient discussion on vaccine candidate safety.

What we've seen non-immunized communities do for previously eradicated outbreaks.

The logistics of supplying the vaccine are being handled by a collaboration of federal agencies. The DoD, parts of HHS, and CDC are coordinating supply, production, and distribution.

Upping the phase 3 investigational vaccine trial size to 44,000 participants will also allow for the enrollment of new populations.

A quick debrief of the week’s top FDA approvals, FDA authorizations, or other infectious disease pipeline developments from the past week.

A new study in The Lancet maps trends in vaccine confidence around the world.

Heat Biologics CEO Jeff Wolf talks with Contagion about the firm's effort to develop a vaccine for the coronavirus which can potentially be administered for some seniors by taking advantage of prior immune mechanisms.